Mirac proteins
This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
1. A method of preparing a conditionally active biologic protein, the method comprising steps of:
i. selecting the wild-type mammalian biologic protein;
ii. evolving a DNA which encodes the wild-type mammalian biologic protein using one or more evolutionary techniques to create mutant DNAs;
iii. expressing the mutant DNAs to obtain mutant proteins at least one of which exhibits both (a) a decrease in activity in an assay at a normal physiological condition that is within a normal range of the physiological condition at a site of administration of the conditionally active protein to a subject, or at a tissue or organ at a site of action of the conditionally active protein of a subject, when compared to the activity of the wild-type mammalian biologic protein in the assay at the same normal physiological condition, and (b) an increase in activity in an assay under an aberrant condition that deviates from the normal range of the physiological condition at the site of administration of the conditionally active protein, or at the tissue or organ at the site of action of the conditionally active protein, when compared to an activity of the wild-type mammalian biologic protein in the assay at the same aberrant condition;
iv. selecting a mutant protein exhibits both (a) a decrease in activity in the assay at the normal physiological condition when compared to the activity of the wild-type mammalian biologic protein in the assay at the same normal physiological condition, and (b) an increase in activity in the assay under the aberrant condition when compared to the activity of the wild-type mammalian biologic protein in the assay at the same aberrant condition; and
v. producing the conditionally active biologic protein from the mutant protein selected in step (iv) by a technique selected from a protein chemical synthesis technique and a recombinant technique, and
wherein the normal physiological condition and aberrant condition are the same condition selected from the group consisting of temperature, pH, osmotic pressure, osmolality, oxidation and electrolyte concentration.
2. The method of 1 , wherein the conditionally active biologic protein comprises at least one non-natural amino acid.
3. The method of claim 1 , wherein the wild-type mammalian biologic protein is an antibody.
4. The method of claim 1 , wherein the conditionally active biologic protein is a synthetic protein of the mutant protein selected in step (iv) produced by the protein synthesis technique and at least one non-natural amino acid is introduced into the synthetic protein by the protein synthesis technique.
5. The method of claim 1 , where the conditionally active biologic protein is a recombinant protein of the mutant protein selected in step (iv) produced by the recombinant technique and at least one non-natural amino acid is introduced into the recombinant protein by the recombinant technique.
6. The method of claim 1 , wherein the evolving step comprises a technique selected from PCR, error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis, ligase chain reaction, in vitro mutagenesis, ligase chain reaction, oligonucleotide synthesis, and combinations thereof.
7. The method of claim 1 , wherein the expression step comprises expressing the mutant DNAs in a host cell selected from a bacterial cell, a fungal cell, an insect cell, a mammalian cell, adenoviruses, and a plant cell.
8. The method of claim 7 , wherein the insect cell is selected from Drosophila S2 cells and Spodoptera Sf9 cells.
9. The method of claim 7 , wherein the mammalian cell is selected from a Bowes melanoma cell, a COS-7 cell, a C127 cell, a 3T3 cell, a CHO cell, a HeLa cell and a BHK cell.
10. A conditionally active biologic protein prepared by the method of claim 1 , wherein the conditionally active biologic protein is reversibly inactivated at the normal physiological condition.
11. The conditionally active biologic protein of claim 10 , wherein the conditionally active biologic protein comprises at least one non-natural amino acid.
12. A method of preparing a conditionally active biologic protein, the method comprising steps of:
i. selecting the wild-type mammalian biologic protein by screening a library;
ii. evolving the DNA which encodes the wild-type mammalian biologic protein using one or more evolutionary techniques to create mutant DNA;
iii. expressing the mutant DNA to obtain at least one mutant protein that exhibits both (a) a decrease in activity in an assay at a normal physiological condition that is within a normal range of the physiological condition at a site of administration of the conditionally active protein to a subject, or at a tissue or organ at a site of action of the conditionally active protein of a subject, when compared to the activity of the wild-type mammalian biologic protein at the same normal physiological condition, and (b) an increase in activity in an assay under an aberrant condition that deviates from the normal range of the physiological condition at the site of administration of the conditionally active protein, or at the tissue or organ at the site of action of the conditionally active protein, when compared to the activity of the wild-type mammalian biologic protein at the same aberrant condition;
iv. selecting a conditionally active biologic protein exhibits both: (a) a decrease in activity in the assay at the normal physiological condition when compared to the activity the wild-type mammalian biologic protein at the same normal physiological condition, and (b) an increase in activity in the assay under the aberrant condition when compared to the activity the wild-type mammalian biologic protein at the same aberrant condition, and
wherein the normal physiological condition and aberrant condition are the same condition selected from the group consisting of temperature, pH, osmotic pressure, osmolality, oxidation and electrolyte concentration.
13. The method of claim 12 , wherein the library is a cDNA library.
14. The method of claim 12 , wherein the wild-type mammalian biologic protein is an antibody.
15. The method of claim 14 , wherein the library is selected from a polyclonal antibody library, a phage display antibody library, and a monoclonal antibody library.
16. The method of claim 12 , wherein evolving step comprises a technique selected from PCR, error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis, ligase chain reaction, in vitro mutagenesis, ligase chain reaction, oligonucleotide synthesis, and combinations thereof.
17. The method of claim 12 , wherein the expression step comprises expressing the mutant DNA in a host cell selected from a bacterial cell, a fungal cell, an insect cell, a mammalian cell, adenoviruses, and a plant cell.
18. The method of claim 17 , wherein the insect cell is selected from Drosophila S2 cells and Spodoptera Sf9 cells.
19. The method of claim 17 , wherein the mammalian cell is selected from a Bowes melanoma cell, a COS-7 cell, a C127 cell, a 3T3 cell, a CHO cell, a HeLa cell and a BHK cell.
20. A conditionally active biologic protein prepared by the method of claim 12 , wherein the protein is reversibly inactivated at the normal physiological condition.
21. The method of claim 12 , wherein the expressing step comprises expressing the mutant protein using bacteriophage display.
22. The method of claim 14 , wherein the antibody is an antibody fragment.
23. A method of preparing a conditionally active antibody, the method comprising steps of:
i. selecting the wild-type mammalian antibody by screening a library;
ii. evolving the DNA which encodes the wild-type mammalian antibody using one or more evolutionary techniques to create mutant DNA;
iii. expressing the mutant DNA to obtain at least two mutant antibodies that exhibit both (a) a decrease in binding activity in an assay at a normal physiological condition that is within a normal range of the physiological condition at a site of administration of the conditionally active protein to a subject, or at a tissue or organ at a site of action of the conditionally active protein of a subject, when compared to the binding activity of the wild-type mammalian antibody at the same normal physiological condition, and (b) an increase in binding activity in the assay under an aberrant condition that deviates from the normal range of the physiological condition at the site of administration of the conditionally active protein, or at the tissue or organ at the site of action of the conditionally active protein, when compared to the binding activity of the wild-type mammalian antibody at the same aberrant condition;
(iv) selecting mutant antibodies that exhibit both: (a) a decrease in binding activity in the assay at the normal physiological condition when compared to the binding activity of the wild-type antibody at the same normal physiological condition, and (b) an increase in binding activity in the assay under the aberrant condition when compared to the binding activity the wild-type antibody at the same aberrant condition;
(v) recombining the heavy chains and the light chains of the selected mutant antibodies to create recombined mutant antibodies using bacteriophage display; and
(vi) screening the recombined antibodies for at least one said conditionally active antibody that exhibits both: (a) a decrease in binding activity in the assay at the normal physiological condition when compared to the binding activity of the wild-type antibody at the same normal physiological condition, and (b) an increase in binding activity in the assay under the aberrant condition when compared to the binding activity of the wild-type antibody at the same aberrant condition; and
wherein the normal physiological condition and aberrant condition are the same condition selected from the group consisting of temperature, pH, osmotic pressure, osmolality, oxidation and electrolyte concentration.
24. The method of claim 1 , wherein the conditionally active biologic protein has a length shorter than the wild-type mammalian biologic protein.
25. The method of claim 12 , wherein the conditionally active biologic protein has a length shorter than the wild-type mammalian biologic protein.
26. The method of claim 1 , wherein the condition is pH.
27. The method of claim 1 , wherein the condition is temperature.
28. The method of claim 1 , wherein the condition is electrolyte concentration.
29. The method of claim 12 , wherein the condition is pH.
30. The method of claim 12 , wherein the condition is temperature.
31. The method of claim 12 , wherein the condition is electrolyte concentration.